Resumen
Variación precio
24h
Actual
Mínimo
918.8
Máximo
923
Recomendaciones | Comprar |
---|---|
Estimación a 12 meses | +9.53 upside |
Novo Nordisk A-S (Class B) Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
7 ago 2024, 10:13 UTC
Novo Nordisk's Wegovy Sales Disappoint -- 2nd Update
DJ
Leer
7 ago 2024, 06:58 UTC
Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge -- Update
DJ
Leer
12 sept 2024, 13:00 UTC
Senators Target Influencers, Telehealth Firms for Misleading Weight-Loss and Other Drug Promotion -- WSJ
DJ
Leer
12 sept 2024, 11:45 UTC
Novo Nordisk's Obesity Pill Data Confirm Investor Optimism -- Market Talk
DJ
Leer
12 sept 2024, 10:30 UTC
Novo Nordisk's Amycretin Obesity Pill Slightly Disappoints on Safety -- Market Talk
DJ
Leer
11 sept 2024, 12:08 UTC
Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids -- Barrons.com
DJ
Leer
9 sept 2024, 07:56 UTC
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
DJ
Leer
3 sept 2024, 11:09 UTC
Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com
DJ
Leer
27 ago 2024, 05:30 UTC
Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com
DJ
Leer
14 ago 2024, 12:01 UTC
Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk
DJ
Leer
9 ago 2024, 11:30 UTC
Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ
DJ
Leer
9 ago 2024, 07:30 UTC
Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk
DJ
Leer
8 ago 2024, 15:44 UTC
Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ
DJ
Leer
8 ago 2024, 11:36 UTC
Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk
DJ
Leer
8 ago 2024, 07:16 UTC
Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk
DJ
Leer
7 ago 2024, 20:30 UTC
Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here's What to Expect. -- Barrons.com
DJ
Leer
7 ago 2024, 16:39 UTC
Novo Nordisk's Wegovy Sales Disappoint -- Update
DJ
Leer
7 ago 2024, 15:30 UTC
Novo Nordisk's Wegovy Sales Disappoint -- WSJ
DJ
Leer
7 ago 2024, 14:22 UTC
It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ
DJ
Leer
7 ago 2024, 12:28 UTC
Novo Nordisk's Core Products Disappoint -- Market Talk
DJ
Leer
7 ago 2024, 12:04 UTC
Novo Nordisk Execs Were Speaking on a Call After 2Q Earnings
DJ
Leer
7 ago 2024, 11:34 UTC
Novo Nordisk US Head: As Wegovy Volumes Go Up, Prices Will Come Down
DJ
Leer
7 ago 2024, 11:34 UTC
Novo Nordisk CEO: When You Move Into New Sales Channels it Comes With a Discount
DJ
Leer
7 ago 2024, 11:34 UTC
Novo Nordisk CEO: Wegovy Now Covered in 20 States Through Medicaid
DJ
Leer
7 ago 2024, 11:05 UTC
Novo Nordisk Delivers Messy Quarter as Wegovy Misses The Mark -- Market Talk
DJ
Leer
7 ago 2024, 10:55 UTC
Stock Market Madness Highlights This Problem for -2-
DJ
Leer
7 ago 2024, 10:55 UTC
Stock Market Madness Highlights This Problem for Novo Nordisk and Super Micro. And 5 Other Things to Know Today. -- Barrons.com
DJ
Leer
7 ago 2024, 09:07 UTC
Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ
DJ
Leer
7 ago 2024, 08:55 UTC
These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com
DJ
Leer
7 ago 2024, 07:32 UTC
Novo Nordisk Wegovy Sales Disappoint -- Market Talk
DJ
Leer
Novo Nordisk A-S (Class B) Esperado
Precio Objetivo
By TipRanks
Estimación a 12 meses
Media 1,162.73 DKK 9.53%
Máximo 1,550 DKK
Mínimo 720 DKK
De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S (Class B) Dist en los últimos 3 meses.
Consenso
By TipRanks
Comprar
11 ratings
7
Comprar
2
Mantener
2
Vender
De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Novo Nordisk A-S (Class B) Dist en los últimos 3 meses.